Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease.
Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware.
Get the full story at our sister site, Drug Delivery Business News.
The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice.
from MassDevice https://ift.tt/2JRaCNW
Cap comentari:
Publica un comentari a l'entrada